Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


WOBURN, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees.

Visit link:
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Related Posts